thalidomide has been researched along with Cirrhosis, Liver in 11 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide, an anti-angiogenic agent, does not have a good therapeutic effect for advanced hepatocellular carcinoma when used alone." | 9.11 | Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study. ( Bendini, C; Bernardi, M; Cantarini, MC; Cappa, FM; Magini, G; Santi, V; Trevisani, F; Zambruni, A, 2005) |
| "This study was to evaluate the effects of thalidomide on expression of adhesion molecules in liver cirrhosis." | 7.73 | Effects of thalidomide on the expression of adhesion molecules in rat liver cirrhosis. ( Liu, S; Luo, H; Lv, P; Paul, SC; Xiao, Y, 2006) |
| "Lenalidomide is a thalidomide analog used for the treatment of myelodysplastic syndromes, with pleiotropic activities including induction of apoptosis, inhibition of angiogenesis and broad immunomodulatory effects." | 5.39 | Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient. ( Arrivé, L; Carbonell, N; Cervera, P; Dangouloff-Ros, V, 2013) |
| "Thalidomide, an anti-angiogenic agent, does not have a good therapeutic effect for advanced hepatocellular carcinoma when used alone." | 5.11 | Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study. ( Bendini, C; Bernardi, M; Cantarini, MC; Cappa, FM; Magini, G; Santi, V; Trevisani, F; Zambruni, A, 2005) |
| "This study was to evaluate the effects of thalidomide on expression of adhesion molecules in liver cirrhosis." | 3.73 | Effects of thalidomide on the expression of adhesion molecules in rat liver cirrhosis. ( Liu, S; Luo, H; Lv, P; Paul, SC; Xiao, Y, 2006) |
| "Thalidomide seems to be a promising agent that might bring about beneficial changes to the disarrangements of peripheral, hepatic, splanchnic and collateral systems in cirrhosis." | 1.43 | Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats. ( Alan, L; Hsieh, SL; Hsieh, YC; Huang, CC; Lee, KC; Lee, SD; Li, TH; Lin, HC; Tsai, CY; Yang, YY, 2016) |
| "Lenalidomide is a thalidomide analog used for the treatment of myelodysplastic syndromes, with pleiotropic activities including induction of apoptosis, inhibition of angiogenesis and broad immunomodulatory effects." | 1.39 | Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient. ( Arrivé, L; Carbonell, N; Cervera, P; Dangouloff-Ros, V, 2013) |
| "Rat liver cirrhosis was achieved by IP injection of carbon tetrachloride (CCl4) three times weekly for 8 weeks." | 1.34 | Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. ( Luo, HS; Lv, P; Paul, SC; Si, XM; Xiao, YJ; Zhou, XP; Zhou, YH, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Yatsuzuka, K | 1 |
| Murakami, M | 1 |
| Yoshida, S | 1 |
| Utsunomiya, R | 1 |
| Watanabe, T | 1 |
| Sayama, K | 1 |
| Dangouloff-Ros, V | 1 |
| Cervera, P | 1 |
| Carbonell, N | 1 |
| Arrivé, L | 1 |
| Safran, H | 1 |
| Charpentier, KP | 1 |
| Kaubisch, A | 1 |
| Mantripragada, K | 1 |
| Dubel, G | 1 |
| Perez, K | 1 |
| Faricy-Anderson, K | 1 |
| Miner, T | 1 |
| Eng, Y | 1 |
| Victor, J | 1 |
| Plette, A | 1 |
| Espat, J | 1 |
| Bakalarski, P | 1 |
| Wingate, P | 1 |
| Berz, D | 1 |
| Luppe, D | 1 |
| Martel, D | 1 |
| Rosati, K | 1 |
| Aparo, S | 1 |
| Moser, S | 1 |
| Tischer, A | 1 |
| Karpi, A | 1 |
| Schleicher, M | 1 |
| Stavjanik, S | 1 |
| Gschwantler, M | 1 |
| Li, TH | 1 |
| Huang, CC | 1 |
| Yang, YY | 1 |
| Lee, KC | 1 |
| Hsieh, SL | 1 |
| Hsieh, YC | 1 |
| Alan, L | 1 |
| Lin, HC | 2 |
| Lee, SD | 2 |
| Tsai, CY | 1 |
| Chang, CC | 1 |
| Wang, SS | 1 |
| Huang, HC | 1 |
| Lee, FY | 1 |
| Lee, JY | 1 |
| Chen, YC | 1 |
| Garrido Serrano, A | 1 |
| León, R | 1 |
| Sayago, M | 1 |
| Márquez, JL | 1 |
| Cappa, FM | 1 |
| Cantarini, MC | 1 |
| Magini, G | 1 |
| Zambruni, A | 1 |
| Bendini, C | 1 |
| Santi, V | 1 |
| Bernardi, M | 1 |
| Trevisani, F | 1 |
| Lv, P | 2 |
| Paul, SC | 2 |
| Xiao, Y | 1 |
| Liu, S | 1 |
| Luo, H | 1 |
| Luo, HS | 1 |
| Zhou, XP | 1 |
| Xiao, YJ | 1 |
| Si, XM | 1 |
| Zhou, YH | 1 |
| Lima, CB | 1 |
| Iglesias, KB | 1 |
| Andrade, ZA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lenalidomide to Reverse Drug Resistance After Lenvatinib Combined With PD-1 Inhibitors in the First-line Treatment of Advanced HCC ：a Prospective, Exploratory, Single-arm, Open-label, Multi-center Clinical Study[NCT05831969] | Phase 2 | 23 participants (Anticipated) | Interventional | 2023-06-05 | Not yet recruiting | ||
| Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial[NCT00717756] | Phase 2 | 41 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"radiographic response defined as partial response defined by RECIST:At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD~It is noted that while on average the time frame for scans was 4 months, there were two patients who at 32 and 36 months had not progressed." (NCT00717756)
Timeframe: on average about every 2 months until progression, on average about 4 months.
| Intervention | participants (Number) |
|---|---|
| Lenalidomide | 6 |
2 trials available for thalidomide and Cirrhosis, Liver
| Article | Year |
|---|---|
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinom | 2015 |
Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2005 |
9 other studies available for thalidomide and Cirrhosis, Liver
| Article | Year |
|---|---|
Successful treatment of psoriasis vulgaris with apremilast in a patient with decompensated cirrhosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Liver Cirrhosis; Psoriasis; Severity of Illness Ind | 2022 |
Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient.
Topics: Angiogenesis Inhibitors; Focal Nodular Hyperplasia; Humans; Infarction; Lenalidomide; Liver; Liver C | 2013 |
Evidence that thalidomide is effective in recurrent bleeding from watermelon stomach associated with liver cirrhosis.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Gastric Antral Vascular Ectasia; Gastrointestina | 2014 |
Thalidomide Improves the Intestinal Mucosal Injury and Suppresses Mesenteric Angiogenesis and Vasodilatation by Down-Regulating Inflammasomes-Related Cascades in Cirrhotic Rats.
Topics: Cells, Cultured; Down-Regulation; Drug Evaluation, Preclinical; Human Umbilical Vein Endothelial Cel | 2016 |
Chronic thalidomide administration enhances vascular responsiveness to vasopressin in portal-systemic collaterals of bile duct-ligated rats.
Topics: Animals; Bile Ducts; Collateral Circulation; Liver Cirrhosis; Male; Portal System; Rats; Rats, Sprag | 2009 |
Thalidomide treatment in cirrhotic patients with severe anemia secondary to vascular malformations.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; | 2012 |
Effects of thalidomide on the expression of adhesion molecules in rat liver cirrhosis.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Blotting, Western; Cell Adhe | 2006 |
Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway.
Topics: Actins; Animals; Blotting, Western; Cell Nucleus; Cytoplasm; Hydroxyproline; I-kappa B Proteins; Imm | 2007 |
Thalidomide failed to inhibit angiogenesis and fibrosis in hepatic schistosomiasis of the mouse.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Female; Liver; Liver Cirrhosis; Male; Mice | 2007 |